
TO: CITY MANAGER **DATE:** 2010 July 07
FROM: DIRECTOR PLANNING AND BUILDING **FILE:** 49500 20
Reference: REZ #10-02
SUBJECT: REZONING REFERENCE #10-02
PORTION OF 5100 NORTH FRASER WAY
RESPONSE TO PUBLIC HEARING ISSUES

PURPOSE: To respond to issues raised at the Public Hearing for Rezoning Reference #10-02.

RECOMMENDATION:

THAT a copy of this report be sent to the applicant and the speaker at the 2010 June 29 Public Hearing for Rezoning Reference #10-02.

REPORT

1.0 BACKGROUND

On 2010 June 29, a Public Hearing was held for Rezoning Reference #10-02 (see Sketch #1 *attached*). The purpose of the proposed rezoning bylaw amendment is to permit the development of a light-industrial building for the office, manufacturing and storage functions of a pharmaceutical company in accordance with the Glenlyon Concept Plan.

One speaker raised concerns at the Public Hearing with regards to potential environmental risks that might be posed by the products processed at the proposed facility. Council requested a staff report regarding this issue.

This report responds to Council's request.

2.0 ISSUE RAISED

As noted above, one speaker appeared before Council representing a neighbour in the Glenlyon Business Park. The speaker requested information regarding the types of products that would be handled at the proposed facility and the potential environmental risks they might pose. In addition, the speaker expressed concern regarding the potential for a release into the atmosphere or sewer and whether or not a contingency plan exists in the event of such a release.

As stated by the applicant at the Public Hearing, the business operating in the proposed development would be manufacturing encapsulating and packaging nutraceuticals (products such as multi-vitamins and herbal products) and over-the-counter drugs, with all products being in

To: City Manager
From: Director Planning and Building
Re: Rezoning Reference #10-02
Portion of 5100 North Fraser Way
2010 July 07 Page 2

powder form. It was stated that 80% of the products at the facility would be nutraceuticals and 20% would be over-the-counter medications and that these are food grade products as defined by Health Canada.

The Planning and Building Department is now in receipt of a letter dated 2010 July 6 forwarded by the applicant, from PNP Pharmaceuticals who would occupy the proposed facility. The attached letter confirms that the proposed facility will not process any material that may cause environmental concern.

It is also noted that the applicant has indicated that he has discussed the matter with individuals at the neighbouring firm (who had been represented by the speaker at the Public Hearing), and has also offered to take these individuals on a tour of PNP Pharmaceuticals' current operations.

3.0 CONCLUSION


At the Public Hearing held for Rezoning Reference #10-02, an issue was raised regarding possible environmental issues related to the proposed development. As requested by Council at the Public Hearing, this report provides the staff response to this matter.



This is for the information of Council.


B. Luksun, Director
PLANNING AND BUILDING

DR:spf
Attachments

cc: Director Engineering
City Clerk



		PLANNING & BUILDING DEPARTMENT		
DATE: FEB 09 2010		REZONING REFERENCE # 10 -- 02 PORTION OF 5100 NORTH FRASER WAY (Showing Proposed Subdivisions)		
SCALE: 1:3,200				
DRAWN BY: DJ				

Sketch #1



July 6, 2010

Demian Rueter, BA, MEdes
City of Burnaby
604.294.7418

Dear Mr. Rueter,

I understand some concern has been raised over the possible pollutants or contaminants that may be emitted to the surrounding environment by PNP Pharmaceuticals Inc.

I would like to state that in no way is there any possible pollutant or contaminant that could originate from PNP Pharmaceuticals Inc. We manufacture nutraceutical and OTC (over the counter) pharmaceutical products in dry dosage form. We do not manufacture radioactive drugs, liquids, antibiotics, or any other material that may cause a possible environmental concern.

The majority of the products we manufacture are nutraceuticals such as multi-vitamins, proteins, and herbal products, many of which carry an organic certification.

We have more of a concern with the outside air and possible contaminants that may enter our building and can safely state that the air emitted from PNP will be far cleaner than that entering our facility.

I hope this gives greater clarification on our operation and alleviates any concern there may have been with PNP with respect to possible risk to the surrounding environment.

Sincerely,

A handwritten signature in black ink that reads 'Glen North'.

Glen North
President & CEO
PNP Pharmaceuticals Inc.